Identification of most frequent HLA class I antigen specificities in Botswana: Relevance for HIV vaccine design

Human Immunology

Volumn 62, Issue 2, 2001, Pages 146-156

  Novitsky, Vladimir ^a   Flores Villanueva, Pedro O ^b   Chigwedere, Pride ^a   Gaolekwe, Sarah ^c   Bussman, Hermann ^a   Sebetso, Gaseene ^c   Marlink, Richard ^a   Yunis, Edmond J ^b   Essex, Max ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Princess Marina Hospital   (South Africa)

Author keywords

Botswana; HIV 1; HIV 1 vaccine; HLA; Southern Africa

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ALLELE; ANTIGEN SPECIFICITY; ARTICLE; BOTSWANA; DISEASE PREDISPOSITION; DNA SEQUENCE; HAPLOTYPE; HEALTH CARE SYSTEM; HLA TYPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AIDS VACCINES; BOTSWANA; CHILD; CHILD, PRESCHOOL; DNA; EPITOPES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HIV INFECTIONS; HLA ANTIGENS; HUMANS; INFANT; MALE; MIDDLE AGED;

EID: 0035115840     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(00)00236-6     Document Type: Article

References (41)

1. HIV-1 nomenclature proposal
2. HIV vaccines: Where we are and where we are going
3. Analysis of HLA frequencies in population cohorts for design of HLA-based HIV vaccines
4. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection
5. Influence of HLA supertypes on susceptibility and resistance rio human immunodeficiency virus type 1 infection
6. HLA associated diseases
7. New class I and II HLA alleles strongly associated with oppgsite patterns of progression to AIDS
8. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
9. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection
10. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
11. Influence of HLA alleles on the rate of progression of vertically transmitted HIV infection in children: Association of several HLA-DR13 alleles with long-term survivorship and the potential association of HLA-A*2301 with rapid progression to AIDS
12. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection
13. Biological basis of the HLA-B8,DR3-associated progression of acquired immune deficiency syndrome
14. HLA and other host factors in transfusion-acquired HIV-1 infection
15. Nomenclature for factors of the HLA system, 1998
16. Molecular cloning and phylogenetic analysis of HIV-1 subtype C: A set of 23 full-length clones from Botswana
17. Estimation of HLA-A, -B, -DR haplotype frequencies in five racial groups represented in the NMDP donor file
18. HLA-A/B and -DRB1/DQB1 allele-level haplotype frequencies
19. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups
20. HLA disease association and protection in HIV infection among African Americans and Caucasians
21. HLA antigens associated with susceptibility/resistance to HIV-1 infection
22. HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women
23. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection
24. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: An HLA-based vaccine strategy
25. Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana
26. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers: Rgp160 Phase II Vaccine Investigators
27. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais
28. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
29. Recombinant bacillus Calmette-Guerin as a potential vector for preventive HIV type 1 vaccines
30. DNA vaccines: A review
31. HIV-1 DNA vaccines
32. Delivery systems and adjuvants for vaccination against HIV
33. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen
34. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients